文献速递肝胆胰外科围术期管理与 ERAS

新辅助放化疗后病理完全缓解与胰腺癌生存期延长相关

Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
PubMed 文献 · Ann Surg · 2018-01-01

pCR患者中位无病生存期26个月,优于近完全缓解和有限缓解者的12个月;pCR患者中位总生存期超过60个月,显著长于近完全缓解的27个月和有限缓解的26个月。多因素分析显示pCR是DFS和OS的独立预后因素。

要点

  • BR/LA-PDAC新辅助放化疗后pCR发生率约10%,与显著延长的DFS和OS相关
  • pCR患者中位OS超过60个月,近完全缓解和有限缓解者分别为27和26个月
  • pCR是DFS(HR=0.45)和OS(HR=0.41)的独立预后因素

核心结论

  • BR/LA-PDAC患者新辅助放化疗后达pCR者,其生存期显著长于近完全缓解或有限缓解者。

研究设计与样本

  • pCR定义为胰腺或淋巴结中病理学未见存活肿瘤;近完全缓解定义为原发肿瘤小于1 cm且无淋巴结转移。

主要发现

  • 19例(10%)达pCR,29例(16%)达近完全缓解,138例(74%)为有限缓解。
  • pCR患者中位DFS为26个月,优于近完全缓解(12个月,P=0.019)和有限缓解(12个月,P<0.001)。
  • pCR患者中位OS超过60个月,近完全缓解(27个月,P=0.003)和有限缓解(26个月,P=0.001)均较短。

临床怎么用

  • 对于BR/LA-PDAC接受新辅助放化疗后手术的患者,病理达pCR提示预后显著优于近完全缓解或有限缓解。
  • pCR可作为术后生存评估和随访策略制定的重要参考指标。

局限性

  • 单中心回顾性研究,样本来自单一机构的前瞻性维护数据库。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the survival outcome of patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) who have a pathologic complete response (pCR) following neoadjuvant chemoradiation. BACKGROUND: Patients with BR/LA-PDAC are often treated with neoadjuvant chemoradiation in an attempt to downstage the tumor. Uncommonly, a pCR may result. METHODS: A retrospective review of a prospectively maintained database was performed at a single institution. pCR was defined as no viable tumor identified in the pancreas or lymph nodes by pathology. A near complete response (nCR) was defined as a primary tumor less than 1 cm, without nodal metastasis. Overall survival (OS) and disease-free survival (DFS) were reported. RESULTS: One hundred eighty-six patients with BR/LA-PDAC underwent neoadjuvant chemoradiation and subsequent pancreatectomy. Nineteen patients (10%) had a pCR, 29 (16%) had an nCR, and the remaining 138 (74%) had a limited response. Median DFS was 26 months in patients with pCR, which was superior to nCR (12 months, P = 0.019) and limited response (12 months, P < 0.001). The median OS of nCR (27 months, P = 0.003) or limited response (26 months, P = 0.001) was less than that of pCR (more than 60 months). In multivariable analyses pCR was an independent prognostic factor for DFS (HR = 0.45; 0.22-0.93, P = 0.030) and OS (HR=0.41; 0.17-0.97, P = 0.044). Neoadjuvant FOLFIRINOX (HR=0.47; 0.26-0.87, P = 0.015) and negative lymph node status (HR=0.57; 0.36-0.90, P = 0.018) were also associated with improved survival. CONCLUSIONS: Patients with BR/LA-PDAC who had a pCR after neoadjuvant chemoradiation had a significantly prolonged survival compared with those who had nCR or a limited response.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. He J, Blair AB, Groot VP, et al. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? Ann Surg. 2018. PMID: 29334562. doi:10.1097/SLA.0000000000002672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。